Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Dr. H.M. (Hanneke) van Santen

Pediatric endocrinologist
Dr. H.M. (Hanneke) van Santen
Dr HM van Santen, pediatric endocrinologist in the Wilhelmina Children’s Hospital and the Princess Maxima Center, is highly specialized in endocrine consequences of childhood cancer treatment, in pediatric thyroid cancer and childhood craniopharyngioma.
She moved her career in 2013 to Utrecht, the Netherlands to support the Máxima initiative and to coordinate the endocrine care for children with cancer in the Princess Máxima Center. She is clinical investigator in the research program of Child Health, WKZ, UMCU and collaborates closely together with different research groups within the Máxima and is a team-member of the pediatric neuro-oncology group of the Máxima. Internationally, she collaborates closely with the endocrine and late effects department of the St Jude’s Hospital (Dr W Chemaitilly, Dr M Hudson, Dr T Merchant).

Her research program focusses on the endocrine effects of childhood cancer treatment, with special interest for the thyroid and pituitary gland, aiming to preserve an intact endocrine system in children with cancer enabling normal growth and development of the child during and after childhood cancer treatment.

She is chair of the Late Effects of Childhood Cancer International Guideline Harmonization Groups (IGHG) for thyroid and hypothalamic-pituitary disorders, and member of the IGHG working groups for male and female gonadal toxicity and preservation of fertility and metabolic syndrome. She is chair of the Dutch Guideline for Thyroid cancer in children and the coordinator of the ERN Thyroid Tumors in Utrecht. She is member of the SKION craniopharyngioma working group, the SIOP supportive care group, the SIOP low grade glioma working group, the national consortium for Late effects of treatment for childhood thyroid carcinoma, the consortium of the Dexadagen-2 study, the Dutch Growth Hormone Advisory board and has a consultative function for the “Cyberpoli” for thyroid diseases and craniopharyngioma.